Skip to main content
- Smaller Text | + Larger Text

FDA Awards Nearly $3M for TB Research

Printer icon
  • Synopsis: Grant to support research projects that will help with the diagnosis treatment and prevention of tuberculosis (TB) - Published: 2010-10-05. For further information pertaining to this article contact: U.S. Food and Drug Administration.

Main Document

The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).

TB remains a major public health challenge with an increasing prevalence worldwide. Two recent articles published by FDA's Office of Critical Path Programs note that advances are urgently needed in TB drug development to shorten therapy and to treat drug-resistant disease.

"FDA recognized an urgent need for the engagement and leadership of public health institutions to promote this critical, but neglected, area of medical therapeutics," said FDA Commissioner Margaret A. Hamburg, M.D.

Funded with congressional support in FY2010, the following six grantees were chosen from among 30 applications:

Michael Brennan, Ph.D., Aeras Global TB Vaccine Foundation - Discovery of biological and immunological biomarkers for TB vaccines

Ann Ginsberg, M.D., Ph.D., Global Alliance for TB Drug Development - Frozen trials, developing a repository of clinical trial specimens

Khisimuzi Mdluli, Ph.D., Global Alliance of TB Drug Development - Qualifying new preclinical models for the development of tuberculosis drug combinations

Fred Quinn, Ph.D., the University of Georgia Research Foundation Inc. - Development of a diagnostic for latent TB

John T. Belisle, Ph.D., Colorado State University - Small molecule biomarkers for tuberculosis treatment, relapse, and cure

Marc D. Porter, Ph.D., the University of Utah - Development and validation of point-of-care tests for tuberculosis (ultra-sensitive SERS detection technology for low concentration antigens).

Launched in 2004, the Critical Path Initiative is the FDA's strategy for driving innovation in the way medical products are developed, evaluated, and manufactured.

For more information: FDA Critical Path Initiative - www.fda.gov/CriticalPath



Related:

  1. Tuberculosis Facts and Information
  2. New TB Test Will Cut Diagnosis Time





Newsletter

     What will I receive?

Money ChartLoan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.


Abraham LincolnFamous People with Disabilities - Well known people with disabilities and conditions who contributed to society.


Pink awareness ribbonList of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.


Chart IconBlood Pressure Chart - What should your blood pressure be. Also see information on blood group types and compatibility.


  1. Report: Global Learning Disability Partnering 2010 to 2017
  2. 2018 Education Budget Summary and Key Points
  3. Declawing Linked to Aggression and Other Abnormal Behaviors in Cats
  4. Russia Facing Ban From PyeongChang 2018 Paralympics




Citation